Used filter(s): 439 items found

  • Remove all filters
  • Search all: Baseball

Drivers of illicit drug use regulation in Australian sport

3 Feb 2021

Drivers of illicit drug use regulation in Australian sport / Bob Stewart, Daryl Adair, Aaron Smith. - (Sport Management Review 14 (2011) 3; p. 237-245)

  • DOI: 10.1016/j.smr.2011.02.001


Abstract:

Most Australian sport stakeholders not only believe that government regulation is a good thing, but also assume that intervention in the drug-use problem will improve sport's social outcomes and operational integrity. In this paper we examine the regulation of illicit drug use in Australian sport through an interrogation of two cases: the Australian Football League and the National Rugby League. Using Pierre Bourdieu's conceptual frames of social field, capital, and habitus, we aim to secure a clearer understanding of the drivers of Australian sport's illicit drug regulations by (1) identifying those stakeholders who set the drug regulation agenda, (2) revealing the values and dispositions that underpin these regulations, and (3) explaining how dominant stakeholders go about sustaining their position and marginalising those stakeholders with opposing drug regulation claims. Our results show that Australian sport's drug-use regulations are driven by a set of values and dispositions that views sport as an instrument for shaping the character of its participants, and drugs as a threat to sport's moral fabric and good standing. The dominant stakeholders, comprising the Commonwealth Government, its sport agencies, and the major governing bodies for sport, imposed these values and dispositions on peripheral stakeholders by designing a drugs-in-sport social field that yielded capital and power to only those participants who endorsed these values and dispositions. Peripheral stakeholders – including players, their agents, and drug-treatment professionals – who mostly shared different values and dispositions, were sidelined, and denied the opportunity of adding to their already limited supplies of capital, power, and policy making influence.

ADAS Annual Report 2020 (Serbia)

31 Dec 2020

ADAS Annual Report 2020 / Anti-Doping Agency of Serbia (ADAS). - Belgrade : Antidoping Agencija Republike Srbije, 2021

WADA - 2019 Anti-Doping Testing Figures Report

18 Dec 2020

2019 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2020

Contents:

  • Executive Summary - pp. 2-8 (7 pages)
  • Laboratory Report -– pp. 9-37 (28 pages)
  • Sport Report - pp. 38-174 (137 pages)
  • Testing Authority Report - pp. 175-313 (139 pages)
  • ABP Report-Blood Analysis - pp. 314-355 (42 pages)

Report Highlights

  • A 5.5% increase in the overall number of samples analyzed: 263,519 in 2018 to 278,047 in 2019.
  • A slight decrease in the total percentage of Adverse Analytical Findings (AAFs): 1.05% in 2018 (2,774 AAFs from 263,519 samples) to 0.97% in 2019 (2,702 AAFs from 278,047 samples).
  • About 60% of WADA-accredited Laboratories saw an increase in the total number of samples recorded.
  • An almost similar total number and percentage of non-Athlete Biological Passport (ABP) blood samples analyzed: 9.3% in 2018 (24,495 of 263,519) and 9.1% in 2019 (25,339 of 278,047).
  • An increase of 16% in the number of ABP blood samples tested: 31,265 in 2018 to 36,401 in 2019.
  • An increase in AAFs reported for Erythropoiesis Stimulating Agents (ESAs), Growth Hormone (GH) and Growth Hormone Releasing Factors (GHRFs).

The World Anti-Doping Agency (WADA) has published its 2019 Testing Figures Report (2019 Report), which summarizes the results of all the samples WADA-accredited Laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2019.

This is the fifth set of global testing figures under the version of the World Anti-Doping Code (Code) that came into effect in January 2015. The 2019 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples; blood and ABP blood data; and, the resulting AAFs and Atypical Findings (ATFs).

WADA - 2018 Anti-Doping Rule Violations (ADRVs) Report

10 Dec 2020

2018 Anti-Doping Rule Violations (ADRVs) Report / World Anti-Doping Agency (WADA). - Montreal : WADA, 2020. - Report compiled based on decisions received by WADA before 2 March 2020


  • The Report highlights 1,923 confirmed Anti-Doping Rule Violations (ADRVs) in 2018, involving individuals from 117 nationalities and across 92 sports
  • 1,640 ADRVs came from Adverse Analytical Findings and 283 from non-analytical, evidence-based intelligence

The World Anti-Doping Agency (WADA) has publishes its sixth annual Anti-Doping Rule Violations (ADRVs) Report, which is the official set of such figures under the World Anti-Doping Code. As usual, the Report is available in a PDF version as well as a dynamic, Excel version that illustrates the ADRV results in an interactive fashion.

The Report illustrates doping offences committed in global sport during 2018. It highlights that there were a total of 1,923 ADRVs recorded in that year. This represents a 6.5% increase relative to the 2017 figure of 1,804, which in turn was 13% more than 2016.

1,640 of the ADRVs came out of Adverse Analytical Findings (AAFs), commonly known as ‘positive’ results. The remainder were derived from investigations and evidence-based intelligence into 267 violations committed by athletes and 16 by athlete support personnel (ASP).

The report contains all ADRV decisions reported to WADA by Anti-Doping Organizations (ADOs). These decisions include those from AAFs reported in samples collected by ADOs in 2018 as well as from non-analytical ADRV decisions rendered in 2018.

As with previous years, the beginning of the report comprises an introduction and an executive summary highlighting key data. The first and second sections present the Results Management outcomes (including ADRVs) of all AAFs detected by WADA-accredited Laboratories for samples collected in 2018 from athletes in- and out-of-competition. They are presented by sport, discipline (Section 1) and testing authority (Section 2).

Section 3 includes ADRVs that resulted from non-analytical findings committed by athletes (presented by sport and nationality) and by ASP (presented by nationality).

Section 4 indicates the total number of ADRVs in 2018, which includes AAFs that resulted in an ADRV plus all non-analytical ADRVs. It presents the data by sport and nationality. It is further broken down into type of samples (urine or blood), type of test (in- or out-of-competition) and athlete gender.

RUSADA Annual Report 2019 (Russia)

29 Oct 2020

Annual Report 2019 / Russian Anti-Doping Agency (RUSADA). - Moscow : Российское антидопинговое агентство (РУСАДА), 2020

SAIDS Annual Report 2019-2020 (South Africa)

22 Oct 2020

Annual Report 2019-2020 / South African Institute for Drugfree Sport (SAIDS). - Cape Town : SAIDS, 2020

  • ISBN: 978-0-621-48869-2

CCES Annual Report 2019-2020 (Canada)

21 Oct 2020

Annual report 2019-2020 / Canadian Centre for Ethics in Sport (CCES). - Ottawa : CCES, 2020

Contents:

  • Our Message to You
  • Governance and Leadership
  • Activate
  • Advocate
  • Protect
  • Doping Control Statistics
  • Financial Report

ASADA Annual Report 2019-2020 (Australia)

15 Oct 2020

Australian Sports Anti-Doping Authority 2019-20 annual report
Australian Sports Anti-Doping Authority (ASADA). - Canberra : ASADA, 2020

Contents:

  • Ceo Message
  • Overview
  • Annual Performance Statement
  • 2019-2020 Strategic Priorities
  • Management and Accountability
  • Financial Statements
  • Anti-Doping Rule Violation Panel
  • Australian Sports Drug Medical Advisory Committee
  • Appendixes, Abbreviations, Glossary
  • Indexes
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin